Log in to search using one of your social media accounts:


Antipsychotic Polypharmacy With Risperidone and Olanzapine Antipsychotic Polypharmacy With Risperidone and Olanzapine

Given high rates of treatment failure for initial therapy of schizophrenia, is combining risperidone and olanzapine an appropriate approach to improve clinical response and limit adverse effects?Medscape Pharmacists
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pharmacist Ask the Expert Source Type: news

Related Links:

Patients who have experienced first-episode psychosis (FEP) appear to have significantly lower levels of folate and vitamin D in their blood compared with individuals with no psychiatric diagnosis, according to areport inSchizophrenia Bulletin.Understanding nutritional deficits that exist from illness onset could lead to nutrient-based interventions to improve diet and possibly reduce symptoms in people with FEP, the authors wrote.Previous studies have suggested that individuals with schizophrenia have low levels of B vitamins (B12 and folate), antioxidant vitamins (C and E), and vitamin D. However, which nutritional defic...
Source: Psychiatr News - Category: Psychiatry Tags: first-episode psychosis folate Joseph Firth nutrition Schizophrenia Bulletin vitamin C vitamin D Source Type: research
Hans C. Klein
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
In conclusion, oral coadministration of CBS with haloperidol resulted in a synergistic effect in rats. The enhanced oral bioavailability of haloperidol when combined with CBS might be attributed to the interaction between them. PMID: 29225304 [PubMed - as supplied by publisher]
Source: Experimental Animals - Category: Research Tags: Exp Anim Source Type: research
Gene-edited human embryo. Self-driving trucks. Practical quantum computers. 2017 has been an exciting year for science, technology – and digital health! It’s that time of the year again when it’s worth looking back at the past months; and list the inventions, methods and milestone events in healthcare to get a clearer picture what will shape medicine for the years to come. 2017 – Amazing year for science and healthcare Scientists, researchers, and innovators come up with amazing breakthroughs every year, and that was no different in 2017 either. No matter whether we look at physics (proving the exis...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine 3d printing artificial intelligence digital health genetics genomics Healthcare Innovation Personalized medicine robotics technology wearables Source Type: blogs
In this study, we propose an alternate approach, known as gray matter surface based spatial statistics (GS-BSS), to perform statistical analysis using gray matter surfaces by incorporating established methods of registration techniques of GM surface segmentation on structural images. Diffusion microstructure features from NODDI and GM surfaces are transferred to standard space. All the surfaces are then projected onto a common GM surface non-linearly using diffeomorphic spectral matching on cortical surfaces. Prior post-mortem studies have shown reduced dendritic length in prefrontal cortex region in schizophrenia and bipo...
Source: MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention - Category: Radiology Tags: Med Image Comput Comput Assist Interv Source Type: research
(Brain&Behavior Research Foundation) The Brain&Behavior Research Foundation awards its Distinguished Investigator Grants valued at $1.7 million to 17 scientists, who are full professors or the equivalent, conducting innovative projects in diverse areas of neurobiological and behavioral research. Recipients of the $100,000, one-year grants are seeking new potential targets for understanding and treating a wide range of neuropsychiatric disorders that affect one in five people, including depression, post-traumatic stress disorder (PTSD), eating disorders, schizophrenia, and psychosis.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: Available online 12 December 2017 Source:Neuroscience & Biobehavioral Reviews Author(s): Martien J. Kas, Brenda Penninx, Bernd Sommer, Alessandro Serretti, Celso Arango, Hugh Marston The current nosology of neuropsychiatric disorders allows for a pragmatic approach to treatment choice, regulation and clinical research. However, without a biological rationale for these disorders, drug development has stagnated. The recently EU-funded PRISM project aims to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases to accelerate the discovery and deve...
Source: Neuroscience and Biobehavioral Reviews - Category: Neuroscience Source Type: research
Theta-phase gamma-amplitude coupling (TGC) was used as an evidence-based tool to reflect the dysfunctional cortico-thalamic interaction in patients with schizophrenia. The aim of the present study was to evaluate the diagnostic utility of TGC. The subjects included 90 patients with schizophrenia and 90 healthy controls. We compared the TGC results between the groups using an analysis of covariance (ANCOVA) to adjust for age and sex and receiver operator characteristic (ROC) curve analyses to examine the discrimination ability of delta to gamma frequency bands and TGC.
Source: Psychiatry Research - Category: Psychiatry Authors: Source Type: research
The AAA+ adenosine triphosphatase (ATPase) Thorase plays a critical role in controlling synaptic plasticity by regulating the expression of surface α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). Bidirectional sequencing of exons of ATAD1, the gene encoding Thorase, in a cohort of patients with schizophrenia and healthy controls revealed rare Thorase variants. These variants caused defects in glutamatergic signaling by impairing AMPAR internalization and recycling in mouse primary cortical neurons. This contributed to increased surface expression of the AMPAR subunit GluA2 and enhanced synapt...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Reports Source Type: research
Condition:   Schizophrenia Interventions:   Drug: Methotrexate;   Other: Placebo Arm Sponsor:   Sheba Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Health | Risperdal Consta | Schizophrenia | Zyprexa